Refine by
Health Threat Articles & Analysis: Older
54 news found
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its Zika Virus Animal Model services for scientists to understand the complex mechanisms of Zika virus infection and develop effective countermeasures. These models are valuable tools in the research and development of vaccines and therapeutics against this emerging ...
Profacgen, a leading provider of custom biotechnology services, is pleased to announce significant updates to its Antimicrobial Peptides (AMPs) Services, enhancing its capabilities to support the growing demand for alternative therapies in the fight against drug-resistant pathogens. As antibiotic resistance continues to pose a global health threat, Profacgen is expanding its services to assist ...
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are major global health threats. Their interaction worsens disease severity, as HIV reduces CD4+ T cells, making individuals more vulnerable to TB. Despite progress, an effective animal model that mimics human immune response during HIV/TB co-infection has been lacking, hindering treatment and vaccine development. Bohorguez et al. ...
Lumen Bioscience — a clinical stage biopharmaceutical company developing biologic drugs for highly prevalent diseases — announced today preliminary results from a Biomedical Advanced Research and Development Authority (BARDA)-supported effort to develop an intranasal formulation of its drug candidate, LMN-301. This drug, produced in spirulina, contains an antibody cocktail for ...
Orginally published by https://www.globenewswire.com/ Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. Emergent will begin the planning phase, the first ...
Today, the Baker-Polito Administration announced that more than $1.5 million has been awarded to four projects that seek to increase testing capacity and provide solutions for coronavirus testing. The funding is through the Accelerating Coronavirus Testing Solutions (A.C.T.S.) Program, designed and administered by the Massachusetts Life Sciences Center, which supports projects focused on two core ...
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. N8 Medical is encouraged by preliminary study data and believes that the CeraShield™ ETT will demonstrate safety and a significant ...
Liaison Memed Bv is an immune system based protein signature test for distinguishing between bacterial and viral infections The test was developed following the licensing agreement signed with Memed as announced in September 2020 The new test is available on the Liaison Xl platforms in countries that accept CE mark and U.S. food and drug administration clearance is planned for 2022 ...
ByMeMed
ApiJect Holdings, Inc., the parent company of ApiJect Systems, Corp., a medical technology public-benefit corporation transforming the fill and finish and delivery of injectable vaccines and medicines, announced today that it had completed a $111 million private round of investment. This investment round values ApiJect at approximately $300 million. The new round was led by Royalty Pharma and ...
THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, today announced that preclinical data from ZIP1642, its COVID-19 vaccine candidate, was published in the renowned scientific journal Molecular Therapy. The paper entitled ...
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced it has raised $50 million in Series C financing to support the U.S. commercial launch of its Next-Generation Phenotyping (NGP) rapid Antimicrobial Susceptibility Testing (AST) platform. "This Series C funding allows us to build out our ...
FDA Orphan Drug Designation (ODD) underscores strength of Atriva’s pipeline and high need for treatments for rare and neglected tropical diseases ODD allows Atriva to benefit from various incentives to develop zapnometinib (ATR-002) against hantavirus infections, and may result in seven-year market exclusivity on approval for this indication Targeting RNA viruses like hantavirus and ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been invited to present at the BARDA Industry Day being held virtually Nov. 3-4, 2021. The Biomedical Advanced Research and Development Authority (BARDA) is a component of the Office of the Assistant ...
Since the emergence of SARS-CoV-2, public health laboratories and researchers have been developing surveillance methods using wastewater to control the spread of COVID-19. The effort has helped identify asymptomatic carriers on college campuses to monitor regional spread among communities and capture emerging mutations ahead of potential future outbreaks. To support these efforts, Thermo Fisher ...
Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. ...
The Denver Regional Council of Governments (DRCOG) has partnered with Denver-based Nymbl Science, the leader in digital, scalable fall prevention for older adults, to provide a free technology solution aimed at reducing the risk of falls for 5,000 older adults ages 60 and up in the Denver-metro area. Nymbl’s at-home digital balance training solution is scientifically proven and has been ...
The demand for telehealth in the United States has grown considerably in the past ten years. In 2017, patients were waiting an average of nearly 30 days to see their doctor, whose accessibility is growing increasingly scarce. It’s little wonder that from 2010-2017, the use of telehealth in hospitals increased from 35% to 76%, with nearly every state Medicaid program covering various ...
As the world reels from the recent impact of COVID-19, researchers are examining ways that the past can inform current and future pandemic response. The most widely documented historic pandemic is that of the Spanish flu in 1918, and while a different set of viruses means drastically different outcomes, comparing and contrasting past and present scenarios provides helpful insight into ...